Qudexy XR topiramate regulatory update

FDA approved an sNDA from Upsher-Smith for Qudexy XR topiramate as initial monotherapy for partial-onset seizures or primary generalized tonic-clonic seizures in patients ages 2-9. Qudexy XR is market...